PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

17497 U.S. PTC 10/702720

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Inventor(s): Shyjan, Andrew W., et al.

Original (nonprovisional)

For: CHK1 AND USES THEREOF

1.	Type	Λf	Anı	nlica	tion
	JPC	υ.	4 7 [7]	hiica	

()

()

This new application is for a(n)

Design

Plant

	(X)	Divisional.		
	()	Continuation.		
	()	Continuation-in-part (C-I-P).		
		CERTIFICATION UNDER 3	7 C.F.R. SECT	FIONS 1.8(a) and 1.10*
I hereb	by certify t	hat, on the date shown below, this correspon	idence is being:	
		M	IAILING	
×		ted with the United States Postal Service in a issioner for Patents, P.O. Box 1450, Alexand		
		7 C.F.R. SECTION 1.8(a)	·	37 C.F.R. SECTION 1.10*
	with su	officient postage as first class mail.	×	as "Express Mail Post Office to Addressee"
				Mailing Label No. EL961947676US
_			NSMISSION	
	transm	itted by facsimile to the Patent and Tradema	rk Office.	Lun Mann
			Signat	ture
		•	Sean I	Hunziker
Date:_	November	r 6, 2003	(type	or print name of person certifying)
*11/ A D	NING:	Early names on too Glad by "Furning Mail	!!!	annuka of da William North and it all the
~77 A K	INIIVO:	Lach paper or jee filed by Express Mail	musi nave inc	e number of the "Express Mail" mailing label placed

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement

will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

thereon prior to mailing. 37 C.F.R. Section 1.10(b).

- 2. Benefit of Prior U.S. Applicati n(s) (35 U.S.C. Sections 119(e), 120, or 121)
 - [X] The new application being transmitted claims the benefit of prior U.S Application Serial No. 09/340,264 filed June 30, 1999.

3.	Maintenance of	of Cor	nendency	v of Pr	ior An	plication
~.			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	· - P	Darestor.

A.	U	Extension of time in prior application
B.	()	Conditional Petition for Extension of Time in Prior Application
		(complete this item, if previous item not applicable)
	()	A conditional petition for extension of time is being filed in the pending prior application.
		[] A copy of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (if applicable)

[] Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

- 95 Pages of Specification, including
 - 89 Pages of Description
 - 5 Pages of Claims
 - 1 Page of Abstract
- 6 Sheet of Drawings (Figure(s) 1-4B)

[]	The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO
. ,	ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
[x]	Formal

(X) Formal

6.	Addi	Additional Papers Encl sed					
	(x) (x) () () (x) () () () (x)	Information Disclosure Statement (37 C.F.R. Section 1.98)(2 pages) Form PTO-1449 (PTO/SB/08A and 08B)(2 pages) Citations Declaration of Biological Deposit 6 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823) and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f)) Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other: Preliminary Amendment (7 pages)					
7.	Decla	Declaration or Oath (including power of attorney)					
	(X)	(3_ pages) Copy of the executed Declaration, Petition and Power of Attorney filed in prior U.S. Application Serial No. 09/340,264, and a copy of Revocation Transmittal, Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney, Change of Attorney Docket Number, and postcard filed April 3, 2003, in prior U.S. Application Serial No. 09/340,264 (6 pages).					
	[]	Not Enclosed.					
8.	Assig	gnment					
	(X)	Assignment of the invention filed in prior U.S. Application Serial No. 09/340,264 to Millennium Pharmaceuticals, Inc., a copy of which [X] is enclosed (6 pages). [] will follow.					

9. Fee Calculation (37 C.F.R. Section 1.16)

A. (x) Regular application

	-	CLAIMS AS F	ILED		
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	22	- 20 =	2	\$18.00	\$36.00
Independent Claims (37 C.F.R. Section 1.16(b))	3	- 3 =	0	\$86.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$280.00	,		\$0.00

Filing Fee Calculation

\$806.00

[]	Amendment canceling extra claims is enclosed.
()	Amendment deleting multiple-dependencies is enclosed.
()	Fee for extra claims is not being paid at this time.

Practitioner's Docket No.: MPI99-012DV1M 10. **Method of Payment of Fees** Check in the amount of \$ [X]Charge Account No. 501668 in the amount of \$806.00 A duplicate of this transmittal is attached. 11. **Authorization to Charge Additional Fees** The Commissioner is hereby authorized to charge the following additional fees by this (X) paper and during the entire pendency of this application to Account No. 501668. 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees) 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims) 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application) 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a). 37 C.F.R. Section 1.17 (application processing fees) 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b)) 12. **Instructions as to Overpayment** Credit Account No. 501668. Refund 13. **Correspondence Address** Direct all future correspondence to: Customer Number 30405 OR Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 November 6, 2003 MILLENNIUM PHARMACEUTICALS, INC. Kerri Pollard Schray Registration No. 47,066 75 Sidney Street Cambridge, MA 02139

Telephone – (617) 551-3676 Facsimile – (617) 551-8820

(X) Statement Where No Further Pages Added

[X] This transmittal ends with this page.